









Markets
/
Stocks
/
nasdaq-prgo
/

Perrigo Company PLC

PRGO

21.190USD

-0.060-0.28%

Close 10/13, 16:00（ET）Quotes delayed by 15 min

2.92BMarket Cap

LossP/E TTM



Perrigo Company PLC

21.190

-0.060-0.28%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Perrigo Company PLC

Currency: USD Updated: 2025-10-13

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite an average stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Perrigo Company PLC's Score

Industry at a Glance

Industry Ranking

56 / 173

Overall Ranking

152 / 4695

Industry

Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 4 analysts

Buy

Current Rating

33.500

Target Price

+57.65%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Perrigo Company PLC Highlights

StrengthsRisks

Perrigo Company plc is a provider of over the counter (OTC) health and wellness solutions that are designed to enhance individual well-being. Its segments include Consumer Self-Care Americas (CSCA) and Consumer Self-Care International (CSCI). The CSCA segment comprises of its consumer self-care business in the United States and Canada. It primarily provides its customers self-care products that are sold and marketed under the customer's own brands and/or exclusive brands. The CSCI segment comprises of its consumer self-care business outside of the United States and Canada, primarily in Europe and Australia. These products are developed, manufactured, marketed, and distributed by the Company. Its product categories include Upper Respiratory, Pain and Sleep-Aids, Skincare and Personal Hygiene, Digestive Health, and Nutrition. Its primary branded products are sold under brand names Compeed, Dr. Fresh, Firefly, Good Sense, Mederma, Nasonex, Solpadeine, Coldrex, and Physiomer, among others.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 22.19.

Fairly Valued

The company’s latest PE is -36.51, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 145.63M shares, decreasing 14.01% quarter-over-quarter.

Held by Keeley-Teton Advisors, LLC

Star Investor Keeley-Teton Advisors, LLC holds 375.68K shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 0.25.

Financial Health

Currency: USD Updated: 2025-10-13

The company's current financial score is 6.85, which is lower than the Pharmaceuticals industry's average of 7.77. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 1.06B, representing a year-over-year decrease of 0.86%, while its net profit experienced a year-over-year decrease of 92.25%.

Score

Industry at a Glance

Previous score

6.85

Change



Financials

8.22

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

2.58

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

5.76

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.72

Key Metrics

Free cash flow

No Data

Perrigo Company PLC's Company Valuation

Currency: USD Updated: 2025-10-13

The company’s current valuation score is 7.19, which is equal to the Pharmaceuticals industry's average of 7.19. Its current P/E ratio is -36.51, which is -49.12% below the recent high of -18.57 and -2781.40% above the recent low of -1051.98.

Score

Industry at a Glance

Previous score

7.19

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 56/173

No Data

Earnings Forecast

Currency: USD Updated: 2025-10-13

The company’s current earnings forecast score is 7.00, which is lower than the Pharmaceuticals industry's average of 7.78. The average price target for Perrigo Company PLC is 33.50, with a high of 40.00 and a low of 27.00.

Score

Industry at a Glance

Previous score

7.00

Change

Support & Resistance

No Data

Analyst Rating

Based on 4 analysts

Buy

Current Rating

33.500

Target Price

+57.65%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

182

Total

Median

Average

Company name

Ratings

Analysts

Perrigo Company PLC

PRGO

Biogen Inc

BIIB

Amgen Inc

AMGN

Vertex Pharmaceuticals Inc

VRTX

Eli Lilly and Co

LLY

AbbVie Inc

ABBV

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-10-13

The company’s current price momentum score is 6.77, which is higher than the Pharmaceuticals industry's average of 6.76. Sideways: Currently, the stock price is trading between the resistance level at 22.39 and the support level at 20.25, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.79

Change

-0.02

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(3)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

0.083

Neutral

RSI(14)

39.553

Neutral

STOCH(KDJ)(9,3,3)

28.262

Sell

ATR(14)

0.578

High Vlolatility

CCI(14)

-69.693

Neutral

Williams %R

76.042

Sell

TRIX(12,20)

-0.163

Sell

StochRSI(14)

0.000

Oversold

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

21.464

Sell

MA10

21.881

Sell

MA20

21.560

Sell

MA50

22.628

Sell

MA100

24.813

Sell

MA200

25.345

Sell

Institutional Confidence

Currency: USD Updated: 2025-10-13

The company’s current institutional recognition score is 10.00, which is higher than the Pharmaceuticals industry's average of 5.59. The latest institutional shareholding proportion is 105.85%, representing a quarter-over-quarter decrease of 0.16%. The largest institutional shareholder is PRFDX, holding a total of 14.43M shares, representing 10.49% of shares outstanding, with 84.91% increase in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

T. Rowe Price Associates, Inc.

Star Investors

14.43M

+1.01%

The Vanguard Group, Inc.

Star Investors

13.96M

+0.42%

BlackRock Institutional Trust Company, N.A.

11.76M

-0.40%

Dimensional Fund Advisors, L.P.

7.51M

+5.29%

State Street Global Advisors (US)

7.34M

+9.51%

DePrince, Race & Zollo, Inc.

4.56M

-0.17%

Ion Asset Management Israel Ltd

3.82M

+34.71%

Neuberger Berman, LLC

3.71M

-2.34%

Cooke & Bieler, L.P.

3.30M

-6.82%

Sound Shore Management, Inc.

3.29M

+0.08%

Risk Assessment

Currency: USD Updated: 2025-10-13

The company’s current risk assessment score is 6.68, which is higher than the Pharmaceuticals industry's average of 5.11. The company's beta value is 0.43. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.